百克生物
(688276)
| 流通市值：75.12亿 | | | 总市值：75.12亿 |
| 流通股本：4.14亿 | | | 总股本：4.14亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 147,351,373.49 | 605,072,927.68 | 474,442,765.98 | 284,896,170.67 |
| 营业收入 | 147,351,373.49 | 605,072,927.68 | 474,442,765.98 | 284,896,170.67 |
| 二、营业总成本 | 150,517,283.29 | 846,820,195.84 | 628,977,112.72 | 382,049,170.48 |
| 营业成本 | 28,068,885.57 | 160,735,359.98 | 116,695,814.9 | 61,615,318.48 |
| 税金及附加 | 2,678,140.15 | 8,099,464.97 | 5,215,196.72 | 3,690,853.41 |
| 销售费用 | 64,954,327.37 | 389,343,796.85 | 285,454,631.67 | 165,564,616.26 |
| 管理费用 | 21,871,484.56 | 110,708,965.24 | 81,861,124.62 | 57,540,332.9 |
| 研发费用 | 32,348,758.94 | 177,099,616.61 | 138,541,423.72 | 93,166,982.13 |
| 财务费用 | 595,686.7 | 832,992.19 | 1,208,921.09 | 471,067.3 |
| 其中:利息费用 | 1,377,825.03 | 3,903,768.29 | 2,487,560.28 | 1,331,702.97 |
| 其中:利息收入 | 366,265.88 | 3,071,826.7 | 1,330,901.77 | 977,831.18 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -10,220,096.72 | -34,413,580.92 | -24,572,779.88 | -15,297,321.86 |
| 资产处置收益 | 18,737.86 | 63,149.52 | - | - |
| 资产减值损失(新) | -621,434.6 | -71,672,544.95 | -48,614,287.46 | -4,343,250.21 |
| 信用减值损失(新) | 4,100,610.31 | -8,827,374.88 | -2,397,194.88 | 6,727,257.99 |
| 其他收益 | 2,213,820.54 | 24,271,970.14 | 3,397,646.12 | 2,101,741.92 |
| 四、营业利润 | -7,674,272.41 | -332,325,649.25 | -226,720,962.84 | -107,964,571.97 |
| 加:营业外收入 | 130,427.19 | 2,275,986.52 | 23,102,925.46 | 8,668,213.56 |
| 减:营业外支出 | - | 1,853,949.94 | 957,609.43 | 309,641.06 |
| 五、利润总额 | -7,543,845.22 | -331,903,612.67 | -204,575,646.81 | -99,605,999.47 |
| 减:所得税费用 | -4,069,701.56 | -69,322,888.48 | -46,325,126.88 | -26,032,571.43 |
| 六、净利润 | -3,474,143.66 | -262,580,724.19 | -158,250,519.93 | -73,573,428.04 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -3,474,143.66 | -262,580,724.19 | -158,250,519.93 | -73,573,428.04 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -3,474,143.66 | -262,580,724.19 | -158,250,519.93 | -73,573,428.04 |
| 扣除非经常损益后的净利润 | -5,007,428.95 | -279,364,436.15 | -179,726,706.79 | -82,232,410.99 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.01 | -0.64 | -0.38 | -0.18 |
| (二)稀释每股收益 | -0.01 | -0.64 | -0.38 | -0.18 |
| 八、其他综合收益 | -2,189,991.99 | -11,697,785.17 | -9,002,103.61 | -6,633,894.84 |
| 归属于母公司股东的其他综合收益 | -2,189,991.99 | -11,697,785.17 | -9,002,103.61 | -6,633,894.84 |
| 九、综合收益总额 | -5,664,135.65 | -274,278,509.36 | -167,252,623.54 | -80,207,322.88 |
| 归属于母公司股东的综合收益总额 | -5,664,135.65 | -274,278,509.36 | -167,252,623.54 | -80,207,322.88 |
| 公告日期 | 2026-04-22 | 2026-04-22 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |